Parallax Volatility Advisers
BMRN icon

Parallax Volatility Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Parallax Volatility Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,133
Closed -$832K – 1573
2025
Q1 		$999K Buy
14,133
+683
+5% +$45.9K ﹤0.01% 1053
2024
Q4 		$884K Sell
13,450
-5,403
-29% -$362K ﹤0.01% 1360
2024
Q3 		$1.33M Buy
18,853
+3,203
+20% +$268K ﹤0.01% 1274
2024
Q2 		$1.29M Buy
15,650
+4,042
+35% +$337K ﹤0.01% 1180
2024
Q1 		$1.01M Buy
+11,608
New +$1.04M ﹤0.01% 1230
2022
Q3 		– Sell
-604
Closed -$53.8K – 3067
2022
Q2 		$50K Buy
+604
New +$48.1K ﹤0.01% 2470
2020
Q4 		– Sell
-1,203
Closed -$92K – 2473
2020
Q3 		$92K Buy
1,203
+463
+63% +$46.8K ﹤0.01% 2736
2020
Q2 		$91K Sell
740
-25,326
-97% -$2.52M ﹤0.01% 2408
2020
Q1 		$2.2M Buy
26,066
+23,191
+807% +$2M ﹤0.01% 1186
2019
Q4 		$243K Buy
2,875
+1,680
+141% +$127K ﹤0.01% 1962
2019
Q3 		$81K Sell
1,195
-28,494
-96% -$2.19M ﹤0.01% 2014
2019
Q2 		$2.54M Buy
29,689
+4,045
+16% +$346K ﹤0.01% 961
2019
Q1 		$2.28M Buy
25,644
+6,496
+34% +$602K ﹤0.01% 955
2018
Q4 		$1.63M Buy
19,148
+14,689
+329% +$1.4M ﹤0.01% 1132
2018
Q3 		$432K Sell
4,459
-16,368
-79% -$1.63M ﹤0.01% 1468
2018
Q2 		$1.96M Buy
+20,827
New +$1.82M ﹤0.01% 915
2016
Q1 		– Sell
-3,947
Closed -$413K – 2526
2015
Q4 		$413K Buy
+3,947
New +$412K ﹤0.01% 1619
2014
Q2 		– Sell
-21,362
Closed -$1.46M – 4044
2014
Q1 		$1.46M Buy
+21,362
New +$1.57M 0.01% 666

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Parallax Volatility Advisers's BMRN Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 14,133 shares — an estimated $832K sold.

Parallax Volatility Advisers first reported a position in BMRN in Q1 2014 and held it in 18 quarters. The position peaked at $2.54M in Q2 2019. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Parallax Volatility Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 14,133 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $832K.
  • Parallax Volatility Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 18 quarters.
  • Parallax Volatility Advisers's BioMarin Pharmaceuticals position peaked at $2.54M in Q2 2019.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.